TrialJournal of neurodevelopmental disorders2019

A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.

Helen Heussler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.